title: Teriflunomide in the treatment of multiple sclerosis: current evidence and future prospects.
abstract: A number of novel oral agents are now approved for use in relapsing multiple sclerosis (MS). Among these agents, teriflunomide has shown promise with respect to clinical efficacy and safety in relapsing MS patients. In this review we aim to clarify the role of teriflunomide in the context of current and emerging MS treatment options by summarizing relevant points on the use of teriflunomide in MS, with a discussion of teriflunomide's pharmacologic properties, pivotal clinical trials, and safety and tolerability.
authors.affiliation: The MS Clinic at St. Michael's Hospital, Division of Neurology, Department of Medicine, University of Toronto, Shuter 3-003, 30 Bond St, Toronto, ON M5B 1W8, Canada.
authors.forename: Jiwon
authors.initials: J
authors.lastname: Oh
authors.affiliation: St Michael's Hospital, Division of Neurology, Department of Medicine, University of Toronto, Toronto, Canada.
authors.forename: Paul W
authors.initials: PW
authors.lastname: O'Connor
keywords: clinical trials; multiple sclerosis; review; teriflunomide